Board of Directors
Evan Jones, Chairman and CEO
Mr. Jones is the Managing Member of jVen Capital, LLC, a life sciences investment company. Prior to forming jVen Capital, he was co-founder, Chairman and CEO of Digene Corporation, a publicly traded biotechnology company focused on women’s health and molecular diagnostic testing. He is a Board Member of Fluidigm, Inc., Foundation Medicine, Inc., and Veracyte, Inc. Mr. Jones is Vice-Chairman of the Board of the Children’s National Medical Center and a Board Member of the Children’s Research Institute. Mr. Jones is Chairman of the Board for the Campaign for Public Health, an organization dedicated to making public health and prevention a higher national priority. He serves on the Board of Directors of Research!America. He has a BA degree from the University of Colorado and an MBA from The Wharton School, University of Pennsylvania.
Brian G. Atwood, Director
Mr. Atwood specializes in biotechnology investing at Versant. He is a co-founder of Versant Ventures and before this spent four years at Brentwood Venture Capital where, as a general partner, he led investments in biotechnology, pharmaceuticals, and bioinformatics. He also has more than fifthteen years of operating experience in the biotechnology industry, with emphasis on therapeutic products, devices, diagnostics, and research instrumentation.
Prior to launching his career in venture capital, Mr. Atwood was founder, President, and CEO of Glycomed, a publicly traded biotechnology company. At Glycomed, Mr. Atwood concentrated on business development and strategic alliances, closing deals with Eli Lilly & Company, Millipore, Genentech and Sankyo, before leading the sale of Glycomed to Ligand Pharmaceuticals. Prior to this, he co-founded and served as director of Perkin Elmer/Cetus Instruments, a joint venture for robotics automation and genomics research instruments and products later acquired by Perkin Elmer. Under Brian’s management, the venture developed and launched the GeneAmp® Polymerase Chain Reaction (PCR) system, the fundamental DNA amplification innovation responsible for fueling the explosive growth of genomics research. He currently serves as a Board member at the private companies FivePrime Therapeutics, Inc., Veracyte, Inc., OpGen, Inc., PhaseRx, Inc., Immune Design Corp., Groove BioPharma, Inc., and Spark Diagnostics, as well as the public companies, Cadence Pharmaceuticals (CADX), Clovis Oncology, Inc. (CLVS), and Trius Therapeutics, Inc. (TSRX). Brian served on the Board of Directors at Pharmion Corporation (sold to Celgene in 2008).
Mr. Atwood received a Bachelor’s degree in Biological Sciences from the University of California, Irvine; a Master’s degree from the University of California, Davis, and an MBA from Harvard Business School.
Harry J. D’Andrea, Director
Mr. D’Andrea is managing general partner of Valhalla Partners, a venture capital firm, a position he has held since January 2012. He previously served as administrative general partner of Valhalla Partners since June 2002, and was a co-founder of Valhalla Partners in 2002. From June 1999 to February 2002, Mr. D’Andrea was Chief Financial Officer of Advanced Switching Communications, Inc., a Nasdaq-listed company that completed its IPO in October 2000. Prior thereto from 1989 to 1999 he held senior financial positions with a number of privately held and public companies. Mr. D’Andrea is currently a director of four privately held companies and has served on the boards of two publicly traded companies in the past.
He received his B.A. in Foreign Service from The Pennsylvania State University and his MBA from Drexel University.
Timothy J.R. Harris, Ph.D., Director
Dr. Harris is a science and business leader with over 32 years of experience guiding and leading laboratory work and scientists in a range of research areas. He is a molecular biologist and biochemist, and currently serves as the Senior Vice President for Translational Medicine and Technology at Biogen Idec. He was the Chief Technology Officer (CTO) and Director of the Advanced Technology Program (ATP) at SAIC-Frederick, Inc. in Maryland, which operates the National Cancer Institute’s leading center for cancer and AIDS research (now Frederick National Laboratory operated by Leidos Inc.,). He has served as President and Chief Executive Officer (CEO) of Novasite Pharmaceuticals, and founded SGX Pharmaceuticals in 1999 (formerly Structural Genomix), where he built the company to more than 130 employees, raised $85M in capital, and generated more than $20M in revenue during six years as CEO before it was sold to Eli Lilly. Before founding SGX, Dr. Harris was Senior Vice President, Research and Development at Sequana/Axys. He began his career working on animal viruses such as that causing Foot & Mouth Disease and was one of the first molecular biologists at Celltech (now UCB Pharma) in the United Kingdom. He subsequently spent five years at Glaxo Group Research as Director of Biotechnology from 1989 to 1993.
Tim Howe, Director
Mr. Howe is a co-founder of Collinson Howe Venture Partners, Inc. (“CHVP”), the predecessor firm to CHL Medical Partners (“CHL”), which manages $340 million in committed capital focused on early stage investing across the entire spectrum of healthcare. Prior to co-founding CHVP in 1990, Mr. Howe was a Partner at Schroder Ventures in the United States, responsible for co-managing several venture capital and private equity funds since joining Schroders in 1984.
Mr. Howe has been an active investor and board member responsible for numerous private investments in the biotechnology, diagnostics, medical device and services areas, including Innotech, Inc. (NASDAQ: IIII, sold to Johnson & Johnson), Camitro Corporation (sold to ArQule, Inc.), Medicus Insurance Holdings (sold to NORCAL Mutual), RxCentric, Inc. (sold to Allscripts, Inc.), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), and still private companies Care Management Technologies, Inc., Medmark Services, Inc. and Opgen, Inc.
Mr. Howe is a graduate of Columbia College and the Columbia Graduate School of Business, where he has also been an Adjunct Assistant Professor since 1995, teaching venture capital management.
Laurence R. McCarthy, Ph.D., Director
Dr. McCarthy joined Ampersand Capital Partners in 2007 as an Operating Partner and serves as Executive Chairman of Viracor-IBT Laboratories, Chairman of Bako, and as a Director of ATS, Dynex and Magellan. As the Chairman and Chief Technology Officer of Focus Diagnostics, he built Focus from a $2 million business to a leading esoteric lab with over $80 million in revenues by the time of its acquisition by Quest Diagnostics in 2006. Prior to Focus, Dr. McCarthy served in various positions at Boehringer Mannheim and Becton Dickinson.
He holds a Ph.D. in Microbiology from the University of New Hampshire and served on the faculty of Johns Hopkins and at the University of North Carolina.
David M. Rubin, Ph.D., Director
Dr. Rubin is a Managing Director in Merck’s Global Health Innovation fund with a primary focus area on precision medicine. Dr. Rubin has invested in molecular diagnostics, point-of-care diagnostics, imaging, and therapeutic device companies that address unmet needs in oncology, infectious disease, neurology, and cardiovascular disease. He holds board seats at Daktari Diagnostics, electroCore, and Prophecy; and is a board observer at Asuragen and Genome Dx.
Dr. Rubin joined Merck in 2007 as Director of Franchise and Portfolio Management. His primary responsibilities were to oversee the operational support of all Merck Research Laboratories (MRL) disease area franchises and provide portfolio management support to MRL Oncology, including the development of franchise strategies, scenario planning, and portfolio valuation. He joined Merck from Cognia Corporation where he was CEO and President, and helped to develop it into one of the pioneer bioinformatics products company. Previously, he was at The Wilkerson Group/IBM Global Services in a Strategic Management position supporting pharma, biotech, and diagnostics companies.
Dr. Rubin holds a Ph.D. from Temple University in Molecular Biology and a B.A. from SUNY Binghamton in Biology. He was a National Institutes of Health and American Cancer Society Post-Doctoral fellow at Harvard Medical School where he worked on the Ubiquitin Proteasome Pathway. He also received training in post-graduate business at Harvard University.
Misti Ushio, Ph.D., Director
Dr. Ushio is CEO of TARA Biosystems. Prior to TARA Biosystems, Dr. Ushio was Chief Strategy Officer and Managing Director of Harris & Harris Group, which she joined in 2007. Prior to joining Harris & Harris Group, Dr. Ushio worked for Merck & Co. for over 10 years in the BioProcess Research & Development group, which focused on vaccines and biologics development. She also worked as a Technology Licensing Officer at Columbia University.
Dr. Ushio currently serves or has served on the boards of Accelerator-NYC, AgBiome, Enumeral Biomedical, Lodo Therapeutics, Petra Pharma, OpGen, Senova Systems and SynGlyco. Her past investments include BioVex (acquired by Amgen), TetraVitate (acquired by Eastman) and Ancora Pharmaceuticals (acquired by Corden Pharma).
She was graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering).